View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

   reports
AMGN AMGEN INC.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 July 2025 in which we reassessed the appropriateness of the ratings in the context of the rel...

07/18/25 July 18, 2025 1 EN
Pierre FerraguÊ
  • Pierre FerraguÊ
PREMIUM
AMGN AMGEN INC.
NOVN NOVARTIS AG

Are Biotechnologies heading towards a zero-shot future? Key insights f...

We kicked off our AI Transforming Industries series last week. We had a fantastic conversation with Mike Nally, CEO of Generate:Biomedicines on how AI is reshaping biotech and drug discovery.

AMGN AMGEN INC.
NOVN NOVARTIS AG
06/10/25 June 10, 2025 1 EN
Research Team ACF
  • Research Team ACF
PREMIUM
AMGN AMGEN INC.
NOVN NOVARTIS AG ... (+11)

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

AMGN AMGEN INC.
NOVN NOVARTIS AG
MRK MERCK & CO. INC.
LLY ELI LILLY AND COMPANY
SAN SANOFI
MRUS MERUS B V
PFE PFIZER INC.
AZN ASTRAZENECA PLC
GLAXO GLAXOSMITHKLINE PHARMACEUTICALS
TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SUMM.L SUMMIT THERAPEUTICS
04/29/25 April 29, 2025 1 EN
EUR 215.00
NVS.. NOVARTIS AG ADS

Novartis AG: Annual update

Our credit view of this issuer reflects its wide geographical diversification, offset by its largest-selling drug and a degree of event risk.

02/05/25 February 5, 2025 1 EN
EUR 645.00
AMGN AMGEN INC.

Amgen Inc. - September 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

01/06/25 January 6, 2025 1 EN
EUR 645.00
NVS.. NOVARTIS AG ADS

Novartis AG - September 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

12/17/24 December 17, 2024 1 EN
EUR 172.00
AMGN AMGEN INC.

Amgen Inc.: Key facts and statistics - LTM June 2024

A summary company profile, detailing Amgen’s business operations and financial highlights.

10/04/24 October 4, 2024 1 EN
EUR 645.00
NVS.. NOVARTIS AG ADS

Novartis AG - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

10/03/24 October 3, 2024 1 EN
EUR 645.00
AMGN AMGEN INC.

Amgen Inc. - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

09/03/24 September 3, 2024 1 EN
EUR 215.00
AMGN AMGEN INC.

Amgen Inc.: Update following outlook revision to stable from negative

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by its unresolved IRS tax disputes.

08/27/24 August 27, 2024 1 EN
EUR 154.80
AMGN AMGEN INC.

Moody's Ratings affirms Amgen's Baa1 ratings; revises outlook to stabl...

Moody's Ratings (Moody's) affirmed the ratings of Amgen Inc. (Amgen) including the Baa1 senior unsecured notes rating, (P)Baa1 senior unsecured shelf rating, (P)Baa1 senior unsecured medium term note program rating, and Prime-2 commercial paper rating. At the same time, we revised Amgen's outlook to...

08/22/24 August 22, 2024 1 EN
EUR 645.00
NVS.. NOVARTIS AG ADS

Novartis AG - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

06/20/24 June 20, 2024 1 EN
EUR 645.00
AMGN AMGEN INC.

Amgen Inc. - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

06/13/24 June 13, 2024 1 EN
EUR 645.00
AMGN AMGEN INC.

Amgen Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

03/18/24 March 18, 2024 1 EN
EUR 215.00
AMGN AMGEN INC.

Amgen Inc.: Near-term focus on pipeline execution, integration of Hori...

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by unresolved IRS tax disputes

03/14/24 March 14, 2024 1 EN
AMGN AMGEN INC.

Moody's announces completion of a periodic review of ratings of Amgen ...

Moody's Ratings has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 March 2024 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant...

03/13/24 March 13, 2024 1 EN
EUR 172.00
NVS.. NOVARTIS AG ADS

Novartis AG: Key facts and statistics - 2023

A summary company profile, detailing Novartis’s business operations and financial highlights.

03/08/24 March 8, 2024 1 EN
EUR 645.00
AMGN AMGEN INC.

Amgen Inc. - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

11/28/23 November 28, 2023 1 EN
EUR 172.00
AMGN AMGEN INC.

Amgen Inc.: Key facts and statistics - LTM June 2023

A summary company profile, detailing Amgen Inc’s business operations and financial highlights.

09/26/23 September 26, 2023 1 EN
EUR 645.00
AMGN AMGEN INC.

Amgen Inc. - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

09/07/23 September 7, 2023 1 EN
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest
Save

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search
Save

ResearchPool Subscriptions

Get the most out of your insights

Get in touch